EMA restricts use of prostate cancer medicine Radium-223 dichloride

July 27, 2018 – The European Medicines Agency (EMA) has concluded its review of the cancer medicine radium-223 dichloride, and has recommended restricting its use to patients who have had two previous treatments for metastatic prostate cancer (prostate cancer that has spread to the bone) or who cannot receive other treatments. Radium-223 dichloride must also not be used with the medicines abiraterone acetate and the corticosteroid prednisone or prednisolone. Radium-223 … (leggi tutto)